Finally, we recently demonstrated that systemic administration of the synthetic TLR9 agonist protects against intestinal injury and mucositis in radiation-induced gastrointestinal syndrome, without conferring any radioprotection to abdominal tumors [39]. The gene discussed is TLR9; the disease is radiation-induced gastrointestinal mucositis.